A61K 38/45
Transferases
Official title: Transferases (2)
A61K38/45 (Transferases) appears on 1,000 US grants and 1,931 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,000
- Published applications
- 1,931
- Assignees
- 828
- Inventors
- 2,994
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 0 | 0 |
| 1979 | 4 | 0 |
| 1980 | 0 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 6 | 0 |
| 1997 | 8 | 0 |
| 1998 | 16 | 0 |
| 1999 | 12 | 0 |
| 2000 | 16 | 0 |
| 2001 | 16 | 8 |
| 2002 | 19 | 33 |
| 2003 | 23 | 48 |
| 2004 | 14 | 52 |
| 2005 | 13 | 47 |
| 2006 | 15 | 63 |
| 2007 | 13 | 43 |
| 2008 | 16 | 59 |
| 2009 | 14 | 68 |
| 2010 | 21 | 55 |
| 2011 | 27 | 70 |
| 2012 | 26 | 46 |
| 2013 | 37 | 73 |
| 2014 | 39 | 106 |
| 2015 | 54 | 99 |
| 2016 | 52 | 126 |
| 2017 | 53 | 99 |
| 2018 | 58 | 101 |
| 2019 | 50 | 89 |
| 2020 | 73 | 95 |
| 2021 | 52 | 103 |
| 2022 | 54 | 110 |
| 2023 | 39 | 94 |
| 2024 | 44 | 92 |
| 2025 | 48 | 93 |
| 2026 | 46 | 59 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for delivery of agents across the blood-brain barrier29 Sep 2026US 12,747,269 B2The Brigham and Women S Hospital, Inc.
- Inhibiting the RNA methyltransferase METTL3 or its interaction with EIF3H to suppress oncogene translation and tumorigenesis22 Sep 2026US 12,742,021 B2Children's Medical Center Corporation
- Compositions and methods for delivery of RNA1 Sep 2026US 12,721,818 B2Rejuvenation Technologies, Inc.
- Compositions comprising a tweak ligand and methods of using same25 Aug 2026US 12,714,740 B2Children's Hospital Medical Center
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Synthetic mmab genes and aav vectors to treat cobalamin b deficiency8 Oct 2026US 2026/0308538 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Compositions comprising smyd1 and methods of use thereof8 Oct 2026US 2026/0308621 A1
- Composition comprising gv1001 for preventing or treating macular degeneration24 Sep 2026US 2026/0284152 A1GemVax & KAEL Co., Ltd.
- Composition comprising gv1001 for preventing or treating periodontal diseases and disorders caused by periodontal diseases24 Sep 2026US 2026/0284153 A1GemVax & KAEL Co., Ltd.
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- Methods and compositions for polypeptide engineering338US 6,586,182 B1Maxygen, Inc. · 2003
- Supplemented and unsupplemented tissue sealants, methods of their production and use292US 6,054,122 AAmerican National Red Cross · 2000
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010